Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Characterization of in Vitro Metabolites of the Aryl Hydrocarbon Receptor Ligand 6-Formylindolo[3,2-b]carbazole by Liquid Chromatography-Mass Spectrometry and NMR.

Linda Bergander, Niklas Wahlström, Tomas Alsberg, Jan Bergman, Agneta Rannug and Ulf Rannug
Drug Metabolism and Disposition February 2003, 31 (2) 233-241; DOI: https://doi.org/10.1124/dmd.31.2.233
Linda Bergander
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niklas Wahlström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Alsberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Bergman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agneta Rannug
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Rannug
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) exhibits the highest aryl hydrocarbon receptor (AhR) binding affinity reported so far. In different cells, in vitro, both extracts of UV-irradiated tryptophan and the synthesized pure compound FICZ induce a rapid and transient expression of AhR-regulated genes. The transient induction suggests that the biotransformation gene battery induced by AhR activation takes part in a metabolic degradation of the ligand, whereby a low steady-state level is regained. The down-regulation of AhR-regulated gene expression was previously shown to be dependent on cytochrome P450 1A1 (CYP1A1). Metabolism of FICZ generates five major metabolites, which appeared as three peaks (M1-M3) in the high performance liquid chromatography. The aim of the present study was to use rat liver S9 from Aroclor-pretreated rats to produce large enough quantities of FICZ metabolites for structure characterization and to determine their product precursor relationship. NMR analysis of large combined fractions of the metabolites indicated that M3 and M2 contained 2 isomers, respectively. By means of liquid chromatography-mass spectrometry (negative ion electrospray mode) and NMR spectroscopy (by 1H-NMR, correlation spectroscopy, and nuclear Overhauser effect spectroscopy techniques) five metabolites of FICZ were identified, and their structures were elucidated. The molecular weights of the two M3 isomers were 300 and both M2 and M1 compounds demonstrated molecular weights of 316, corresponding to addition of one (M3) and of two oxygen (M2 and M1), respectively. The structures were assigned as 2- and 8-hydroxy (M3), 2,10- and 4,8-dihydroxy (M2) and 2,8-dihydroxy derivatives of indolo[3,2-b]carbazole-6-carboxaldehyde (6-formylindolo[3,2-b]carbazole).

Footnotes

  • Abbreviations used are::
    AhR
    aryl hydrocarbon receptor
    FICZ
    6-formylindolo[3,2-b]carbazole
    bHLH/PAS
    helix-loop-helix/Per-Arnt-Sim
    ICZ
    indolo[3,2-b]carbazole
    DMSO
    dimethyl sulfoxide
    HPLC
    high performance liquid chromatography
    LC-MS
    liquid chromatography-mass spectrometry
    DAD
    diode array detector
    COSY
    correlation spectroscopy
    NOESY
    nuclear Overhauser effect spectroscopy
    ROESY
    rotating frame nuclear Overhauser effect spectroscopy
    Mx
    metabolite fractions 1, 2, or 3
    1
    6-formylindolo[3,2-b]carbazole
    2
    8-hydroxyindolo[3,2-b]carbazole-6-carboxaldehyde
    3
    2-hydroxyindolo[3,2-b]carbazole-6-carboxaldehyde
    4
    4,8-dihydroxylindolo[3,2-b]carbazole-6-carboxaldehyde
    5
    2,10-dihydroxyindolo[3,2-b]carbazole-6-carboxaldehyde
    6
    2,8-dihydroxyindolo[3,2-b]carbazole-6-carboxaldehyde
    • Received April 16, 2002.
    • Accepted October 29, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (2)
Drug Metabolism and Disposition
Vol. 31, Issue 2
1 Feb 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of in Vitro Metabolites of the Aryl Hydrocarbon Receptor Ligand 6-Formylindolo[3,2-b]carbazole by Liquid Chromatography-Mass Spectrometry and NMR.
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of in Vitro Metabolites of the Aryl Hydrocarbon Receptor Ligand 6-Formylindolo[3,2-b]carbazole by Liquid Chromatography-Mass Spectrometry and NMR.

Linda Bergander, Niklas Wahlström, Tomas Alsberg, Jan Bergman, Agneta Rannug and Ulf Rannug
Drug Metabolism and Disposition February 1, 2003, 31 (2) 233-241; DOI: https://doi.org/10.1124/dmd.31.2.233

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of in Vitro Metabolites of the Aryl Hydrocarbon Receptor Ligand 6-Formylindolo[3,2-b]carbazole by Liquid Chromatography-Mass Spectrometry and NMR.

Linda Bergander, Niklas Wahlström, Tomas Alsberg, Jan Bergman, Agneta Rannug and Ulf Rannug
Drug Metabolism and Disposition February 1, 2003, 31 (2) 233-241; DOI: https://doi.org/10.1124/dmd.31.2.233
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mass Balance Recovery and Disposition of AZD4831 in Humans
  • Biotransformation of AZD4831 in Animals and Humans
  • AKRs and GUSs in Testosterone Disposition
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics